By Daniella Parra
Octave Bioscience said it secured a $30 million extension to its Series B funding round.
The investment, led by Novartis, Hikma Ventures and Intermountain Ventures, will accelerate commercialization of their precision care solution for multiple sclerosis (MS) and other neurodegenerative diseases, the company said in a statement.
“The strength and breadth of our investment partners illustrate the impact our solution has across the entire healthcare ecosystem – physicians, payers, pharma, and most importantly, patients,” said William Hagstrom, Octave’s Founder and Chief Executive Officer. “With our multimodal precision care solution, we are providing tools, insights, and a platform that enable a personalized approach to patient care, better treatment decisions and improved outcomes.”
The company, based in Menlo Park, CA, said that the strategic investor mix demonstrates the value and support for its ability to improve patient care in neurodegenerative diseases including Parkinson’s and Alzheimer’s.
Contact:
Editor@Executives-edge.com
